Broadwood Partners Cuts Lineage Cell Therapeutics Stake to 24.9%

TL;DR

**Broadwood Partners just cut its stake in Lineage Cell Therapeutics to 24.9%.**

AI Summary

Broadwood Partners, L.P. filed an Amendment No. 26 to their Schedule 13D, indicating a change in their beneficial ownership of Lineage Cell Therapeutics, Inc. common shares. As of February 6, 2024, Broadwood Partners, L.P. beneficially owns 41,666,255 shares, representing 24.9% of the company's common shares. This is a decrease from their previously reported ownership, which matters to investors as it signals a reduction in a significant institutional holder's stake, potentially impacting stock sentiment and future governance.

Why It Matters

A major institutional investor reducing its stake can signal a loss of confidence or a strategic shift, which could put downward pressure on the stock price or limit its upside.

Risk Assessment

Risk Level: medium — A significant reduction in ownership by a major institutional investor like Broadwood Partners could indicate a negative outlook or a strategic divestment, posing a moderate risk to current and prospective shareholders.

Analyst Insight

A smart investor would monitor Lineage Cell Therapeutics' stock for further institutional selling and evaluate the reasons behind Broadwood Partners' reduced stake, potentially considering a reduction in their own position or holding off on new investments until more clarity emerges.

Key Numbers

• 41,666,255 — Shares Beneficially Owned (This is the total number of common shares of Lineage Cell Therapeutics, Inc. that Broadwood Partners, L.P. now beneficially owns, indicating their reduced stake.)
• 24.9% — Percentage of Class (This represents the percentage of Lineage Cell Therapeutics, Inc.'s common shares that Broadwood Partners, L.P. beneficially owns, a decrease from previous filings.)
• Amendment No. 26 — Filing Amendment Number (This indicates that Broadwood Partners, L.P. has made numerous updates to their Schedule 13D filing regarding Lineage Cell Therapeutics, Inc., suggesting ongoing active management of their position.)

Key Players & Entities

• Broadwood Partners, L.P. (company) — the reporting person reducing its stake
• Lineage Cell Therapeutics, Inc. (company) — the subject company whose shares are being reported
• Neal C. Bradsher (person) — contact person for Broadwood Capital, Inc.
• 41,666,255 (dollar_amount) — number of shares beneficially owned by Broadwood Partners, L.P.
• 24.9% (dollar_amount) — percentage of Lineage Cell Therapeutics, Inc. common shares beneficially owned
• February 6, 2024 (date) — date of the event requiring the filing

Forward-Looking Statements

• Lineage Cell Therapeutics' stock price may experience short-term downward pressure due to the reduced institutional ownership. (Lineage Cell Therapeutics, Inc.) — medium confidence, target: 3 months
• Broadwood Partners, L.P. may continue to gradually reduce its stake in Lineage Cell Therapeutics. (Broadwood Partners, L.P.) — medium confidence, target: 6 months

FAQ

Key Financial Figures

• $7,000,000 — offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share. The for
• $1.04 — tal purchase price of $7,000,000.80, or $1.04 per Common Share. The foregoing is a s

Filing Documents

• d10974070_13d-a.htm (SC 13D/A) — 94KB
• 0000919574-24-000756.txt ( ) — 96KB

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 8, 2024 Broadwood Partners, L.P.* By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, Inc. * By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President /s/ Neal C. Bradsher Neal C. Bradsher * * This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Amendment No. 26 to Schedule 13D, dated February 8, 2024, relating to the Common Shares, no par value, of Lineage Cell Therapeutics, Inc. shall be filed on behalf of the undersigned. Dated: February 8, 2024 Broadwood Partners, L.P. By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President /s/ Neal C. Bradsher Neal C. Bradsher

View Full Filing

View this SC 13D/A filing on SEC EDGAR